p53 Protein Overexpression in Endometrial Carcinoma
Author Information
Author(s): R Soong, S Knowles, KE Williams, IG Hammond, SJ Wysocki, BJ Iacopetta
Primary Institution: University of Western Australia; King Edward Memorial Hospital for Women
Hypothesis
The study investigates the prognostic significance of p53 overexpression and mutation in endometrial carcinoma.
Conclusion
Nuclear p53 overexpression is linked to worse survival, while cytoplasmic p53 overexpression is associated with better survival in endometrial cancer.
Supporting Evidence
- Nuclear p53 overexpression was found in 27% of cases and was associated with a 48% survival rate at 5 years.
- Cytoplasmic p53 overexpression was found in 54% of cases and was associated with an 85% survival rate at 5 years.
- Mutation of the p53 gene was found in 13% of cases but did not significantly correlate with patient survival.
Takeaway
This study found that if a certain protein called p53 is too much in the nucleus of cancer cells, it means the patient might not live as long, but if it's in the cytoplasm, they might live longer.
Methodology
The study analyzed p53 overexpression and mutation in 122 endometrial carcinoma specimens using immunohistochemistry and single-strand conformation polymorphism.
Limitations
The study is limited by its retrospective nature and the potential for selection bias in the patient population.
Participant Demographics
Patients operated for primary endometrial carcinoma from 1979-1987.
Statistical Information
P-Value
P<0.001 for nuclear overexpression; P<0.001 for cytoplasmic overexpression; P=0.115 for mutation.
Confidence Interval
95% CI 1.3-17.6 for nuclear overexpression; 95% CI 0.06-0.98 for cytoplasmic overexpression.
Statistical Significance
p<0.001
Want to read the original?
Access the complete publication on the publisher's website